reports
EQS-News: 2G Energy AG steigert Auftragseingang im 1. Quartal um 26%
EQS-News: 2G Energy AG / Schlagwort(e): Auftragseingänge/Dividende 2G Energy AG steigert Auftragseingang im 1. Quartal um 26% 18.04.2024 / 13:04 CET/CEST Für den Inhalt der Mitteilung ist der Emittent / Herausgeber verantwortlich. 2G Energy AG steigert Auftragseingang im 1. Quartal um 26% Auftragseingang erreicht 51,7 Mio. Euro (Vj.: 41,0 Mio. Euro) US-Markt überwindet Zurückhaltung und zeigt spürbares Wachstum (10,1 Mio. Euro; Vj.: 2,6 Mio. Euro) 2G verkauft in Deutschland die erste BHKW-Wärmepumpen-Kombination Vorstand und Aufsichtsrat schlagen eine Dividendenerhöhu...
EQS-News: 2G Energy AG boosts order intake by 26% in 1st quarter
EQS-News: 2G Energy AG / Key word(s): Incoming Orders/Dividend 2G Energy AG boosts order intake by 26% in 1st quarter 18.04.2024 / 13:04 CET/CEST The issuer is solely responsible for the content of this announcement. 2G Energy AG boosts order intake by 26% in 1st quarter Orders reach EUR 51.7 million (previous year: EUR 41.0 million) US market overcomes caution and shows significant growth (EUR 10.1 million; previous year: EUR 2.6 million) 2G sells its first CHP/heat pump combination in Germany Management and Supervisory boards propose a dividend increase of 21% to EU...
Sun Hung Kai Properties Ltd: 1 director
A director at Sun Hung Kai Properties Ltd bought 601,500 shares at 69.841HKD and the significance rating of the trade was 67/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last tw...
Tongcheng Travel Holdings Limited: 1 director
A director at Tongcheng Travel Holdings Limited sold 360,000 shares at 22.084HKD and the significance rating of the trade was 67/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the las...
The Joint Corp. to Host Conference Call on Thursday, May 2nd to Discus...
The Joint Corp. to Host Conference Call on Thursday, May 2nd to Discuss First Quarter 2024 Results SCOTTSDALE, Ariz., April 18, 2024 (GLOBE NEWSWIRE) -- The Joint Corp. (NASDAQ: JYNT), the nation's largest provider of chiropractic care through The Joint Chiropractic® network, announced it will report its first quarter 2024 financial results on Thursday, May 2, 2024, after the market close. President and CEO Peter D. Holt and CFO Jake Singleton will hold a conference call at 5:00 p.m. EDT that day to discuss the results. Shareholders and interested participants may listen to a live br...
EQS-News: CureVac veröffentlicht am 24. April 2024 Finanzergebnisse de...
Emittent / Herausgeber: CureVac / Schlagwort(e): Sonstiges CureVac veröffentlicht am 24. April 2024 Finanzergebnisse des vierten Quartals sowie des Gesamtjahres 2023 und informiert über seine Geschäftsentwicklung 18.04.2024 / 13:00 CET/CEST Für den Inhalt der Mitteilung ist der Emittent / Herausgeber verantwortlich. CureVac veröffentlicht am 24. April 2024 Finanzergebnisse des vierten Quartals sowie des Gesamtjahres 2023 und informiert über seine Geschäftsentwicklung TÜBINGEN, Germany/BOSTON, USA – 18. April 2024 – CureVac N.V. (Nasdaq: CVAC), ein biopharmazeutisches U...
EQS-News: CureVac to Report Fourth Quarter and Full-Year 2023 Financia...
Issuer: CureVac / Key word(s): Miscellaneous CureVac to Report Fourth Quarter and Full-Year 2023 Financial Results and Business Update on April 24, 2024 18.04.2024 / 13:00 CET/CEST The issuer is solely responsible for the content of this announcement. CureVac to Report Fourth Quarter and Full-Year 2023 Financial Results and Business Update on April 24, 2024 TÜBINGEN, Germany/BOSTON, USA – April 18, 2024 – CureVac N.V. (Nasdaq: CVAC) (“CureVac”), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (“m...
Mawson Infrastructure Group Inc. Announces Monthly Operational Update ...
Mawson Infrastructure Group Inc. Announces Monthly Operational Update for March 2024 Total Revenue Doubled with 100% Y/Y Growth from March of last year March Self-Mining Business Revenue up 182% Y/Y March Co-Location Business Revenue up 54% Y/Y March Total Revenue of about $5.44 million MIDLAND, Pa., April 18, 2024 (GLOBE NEWSWIRE) -- Mawson Infrastructure Group Inc. (NASDAQ:MIGI) (“Mawson” or the “Company”), a digital infrastructure company, announced today its unaudited business and operational update for March 2024. Rahul Mewawalla, CEO and President, commented, “We are very plea...
SpringWorks Therapeutics to Report First Quarter 2024 Financial Result...
SpringWorks Therapeutics to Report First Quarter 2024 Financial Results Thursday, May 2, 2024 STAMFORD, Conn., April 18, 2024 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a commercial-stage biopharmaceutical company focused on severe rare diseases and cancer, today announced that it will host a live conference call and webcast at 8:30 a.m. E.T. on Thursday, May 2, 2024 to report its first quarter financial results and discuss recent business updates. To join the live webcast and view the corresponding slides, please click . To access the live call by phone, please p...
LanzaTech Announces Date for First Quarter 2024 Earnings Release and C...
LanzaTech Announces Date for First Quarter 2024 Earnings Release and Conference Call CHICAGO, April 18, 2024 (GLOBE NEWSWIRE) -- LanzaTech Global, Inc. (Nasdaq: LNZA) (“LanzaTech” or the “Company”), the carbon recycling company transforming waste carbon into sustainable raw materials, today announced that it will issue its first quarter 2024 financial results before the market opens on Thursday, May 9, 2024. A conference call will be held that same day at 8:30 A.M. ET to review the Company's financial results, discuss recent events and conduct a question-and-answer session. The confe...
Ocular Therapeutix™ Announces Positive Topline Phase 1 Data for AXPAXL...
Ocular Therapeutix™ Announces Positive Topline Phase 1 Data for AXPAXLI™ in Diabetic Retinopathy 46.2% of patients demonstrated a 1- or 2-step improvement in the Diabetic Retinopathy Severity Scale (DRSS) at 40 weeks in the AXPAXLI arm, compared to 0% in the control arm No patients in the AXPAXLI group experienced worsening in DRSS compared to 12.5% in the control arm at 40 weeks AXPAXLI was generally well tolerated with no inflammation observed Ocular intends to present the Phase 1 HELIOS study at an upcoming meeting BEDFORD, Mass., April 18, 2024 (GLOBE NEWSWIRE) -- Ocular Therapeut...
Benitec Biopharma Announces Oversubscribed Private Placement Financing...
Benitec Biopharma Announces Oversubscribed Private Placement Financing of $40.0 Million HAYWARD, Calif., April 18, 2024 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (NASDAQ: BNTC) (“Benitec” or the “Company”), a clinical-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on its proprietary “Silence and Replace” DNA-directed RNA interference (“ddRNAi”) platform, today announced a $40.0 million private investment in public equity (PIPE) financing from the sale of 5,749,152 shares of its common stock at a price per share of $4.80, and, in lieu of shares...
Agios to Webcast Conference Call of First Quarter 2024 Financial Resul...
Agios to Webcast Conference Call of First Quarter 2024 Financial Results on May 2, 2024 CAMBRIDGE, Mass., April 18, 2024 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in cellular metabolism and PK activation pioneering therapies for rare diseases, today announced the company will host a conference call and live webcast on Thursday, May 2, 2024, at 8:00 a.m. ET to report its first quarter 2024 financial results and other business highlights. A live webcast of the presentation can be accessed under "Events & Presentations" in the Investors section of the company'...
OMNI-LITE INDUSTRIES REPORTS FOURTH QUARTER AND FISCAL 2023 RESULTS AN...
OMNI-LITE INDUSTRIES REPORTS FOURTH QUARTER AND FISCAL 2023 RESULTS AND CONFERENCE CALL FOR INVESTORS: APRIL 19, 2024, AT 11:00 AM EDT Fiscal 2023 Marks a Return to Organic Revenue Growth and Positive EBITDA(1)Record Breaking Backlog of US$7.0 million, Almost Doubling the Prior Year PerformanceQ1 of Fiscal 2024 Expected to Show Strong Revenue Growth TSXV: OML OTCQX: OLNCF LOS ANGELES, CALIFORNIA, April 18, 2024 (GLOBE NEWSWIRE) -- Omni-Lite Industries Canada Inc. (the "Company" or “Omni-Lite”; TSXV: OML) today reported results for the fourth quarter and fiscal year ending December 31, 2...
Lantronix Case Study focuses on Reliable and Secure Support Provided t...
Lantronix Case Study focuses on Reliable and Secure Support Provided to Financial Services Industry by its Out-of-Band Solutions Case Study: Lantronix OOB solutions enhance secure automation of critical banking infrastructure IRVINE, Calif., April 18, 2024 (GLOBE NEWSWIRE) -- (NASDAQ: LTRX), a global provider of compute and connectivity IoT solutions announced that it published today its case study focusing on deployment of its Out-of-Band () solutions and accompanying Level Technical Services by a leading financial services company. This large global entity has a complex IT infrastruc...
Aesthetic Medical International to Announce FY2023 Annual Report on Ap...
Aesthetic Medical International to Announce FY2023 Annual Report on April 25, 2024 SHENZHEN, China, April 18, 2024 (GLOBE NEWSWIRE) -- Aesthetic Medical International Holdings Group Limited (Nasdaq: AIH) (the “Company” or “AIH”), a leading provider of aesthetic medical services in China, today announced that it will release its annual report for the fiscal year of 2023 after the U.S. market closes on Thursday, April 25, 2024. About Aesthetic Medical International Holdings Group Limited AIH, known as “Peng’ai” in China, is a leading provider of aesthetic medical services in China. AIH ope...
Chemomab Reports New Peer-Reviewed Publication Reinforcing the Clinica...
Chemomab Reports New Peer-Reviewed Publication Reinforcing the Clinical Association of Its CCL24 Target with Disease Severity and Mortality in Patients with Systemic Sclerosis —Longitudinal Study of a 200+ Real-World Patient Cohort Further Validates CCL24 as a Novel Target for Systemic Sclerosis (SSc), Showing that It is Associated with Disease Severity Across the Fibrotic and Vascular Manifestations of SSc— TEL AVIV, Israel, April 18, 2024 (GLOBE NEWSWIRE) -- Chemomab Therapeutics Ltd. (Nasdaq: CMMB), (Chemomab), a clinical stage biotechnology company developing innovative therapeutics ...
Bacchus Capital Engaged as Strategic & Project Funding Adviser
Bacchus Capital Engaged as Strategic & Project Funding Adviser TORONTO, April 18, 2024 (GLOBE NEWSWIRE) -- Xanadu Mines Ltd (ASX: XAM, TSX: XAM) (Xanadu, XAM or the Company) is pleased to announce that it has engaged Bacchus Capital Advisers Limited (Bacchus) as its strategic and project funding adviser in relation to the Kharmagtai Copper-Gold Project in the South Gobi region of Mongolia. Highlights Xanadu is executing a Pre-Feasibility Study (PFS) at its Kharmagtai copper-gold project, a 50-50 joint venture with Zijin Mining Group Co Ltd (Zijin). The PFS will be completed in Q3 CY2024...
TG Therapeutics Awarded National Contract by the Department of Veteran...
TG Therapeutics Awarded National Contract by the Department of Veterans Affairs for BRIUMVI as the Preferred Anti-CD20 for Relapsing Forms of Multiple Sclerosis NEW YORK, April 18, 2024 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), announced that it has been awarded a national contract with the Department of Veterans Affairs (VA) for BRIUMVI® (ublituximab-xiiy) to be the preferred agent listed on the VA National Formulary for Anti-CD20 Antibody indications for patients with relapsing forms of multiple sclerosis (RMS). Michael S. Weiss, Chief Executive Officer and Chairman of ...
Tiziana Life Sciences Announces New Quantitative PET Imaging Data on F...
Tiziana Life Sciences Announces New Quantitative PET Imaging Data on Foralumab at the Annual Meeting of the American Academy of Neurology Oral presentation of study shows intranasal foralumab attenuates microglial activation and disease progression in multiple sclerosis (MS) patients with PIRA as measured by changes in PET scans NEW YORK, April 18, 2024 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies via novel routes of drug delivery, today announces a platform present...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.